Addressing the knowledge gaps surrounding AMR infections in neonatal sepsis

  04 July 2021

While progress in reducing the rate of child mortality since the launch of the Millennium Development Goals in 1990 has been promising, improvements in reducing neonatal mortality have been far slower. Infections in the neonatal period are one of the major contributors to an ongoing high rate of neonatal morbidity and mortality worldwide. In an era of increasing antimicrobial resistance (AMR), the burden of infections caused by multidrug-resistant (MDR) bacteria resistant to the current WHO empirical therapeutic guidelines is resulting in a persistently unacceptably high rate of perinatal and infant mortality globally.

Further reading: Revive
Author(s): Phoebe Williams, Nina Putri and Gayana Gunaratna
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

CDD VAULT Complexity Simplified





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!